Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris
Sarecycline is a novel, narrow-spectrum, once-daily tetracycline-derived oral antibiotic that is FDA-approved in the US to be taken with or without food for moderate-to-severe acne vulgaris for ages 9 years of age and older. Sarecycline possesses anti-inflammatory properties and potent activity agai...
Gespeichert in:
| Veröffentlicht in: | Future microbiology 2019-09, Vol.14 (14), p.1235-1242 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1242 |
|---|---|
| container_issue | 14 |
| container_start_page | 1235 |
| container_title | Future microbiology |
| container_volume | 14 |
| creator | Moore, Angela Yen Charles, Jean Elizze M Moore, Stephen |
| description | Sarecycline is a novel, narrow-spectrum, once-daily tetracycline-derived oral antibiotic that is FDA-approved in the US to be taken with or without food for moderate-to-severe acne vulgaris for ages 9 years of age and older. Sarecycline possesses anti-inflammatory properties and potent activity against Gram-positive bacteria, including activity against multiple strains of
, while exhibiting minimal activity against enteric aerobic Gram-negative bacteria. Unlike many acne studies, sarecycline was investigated for chest and back acne. Significant reduction in inflammatory lesions was seen at week 12 at 1.5 mg/kg/day of sarecycline, with statistically significant improvement seen as early as week 3. No reports of phototoxicity, dizziness, pseudotumor cerebri or lupus but 1.2% nausea and 1.2% vaginal candidiasis was reported in the pivotal Phase III studies. |
| doi_str_mv | 10.2217/fmb-2019-0199 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6802708</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2283289472</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-1235d06e0b7864514fcba4604e668109b45b5e9e8f495d2d6f193dd31e8a80143</originalsourceid><addsrcrecordid>eNp1kc9vFCEUx4mxsbV69GpIvHgZBQYY8GDSNP5KmvTQeiYM82inmRnWB7Om_71sdt2oiQcC5H345j0-hLzi7J0QvHsf574RjNumLvuEnPFO6oZZwZ8ez7w9Jc9zfmBMGW75M3Lactkpo80Z8TceITyGaVzgA_V08YjpJ80bCAXXmRYo6A91GhPScg-0IPgyw1JoinROA6Av0JTUZNgCAvWhwtt1uvM45hfkJPopw8vDfk6-f_50e_m1ubr-8u3y4qoJUqvScNGqgWlgfWe0VFzG0HupmQStDWe2l6pXYMFEadUgBh25bYeh5WC8YVy25-TjPnez9jMMobaHfnIbHGePjy750f1dWcZ7d5e2ThsmOmZqwNtDAKYfK-Ti5jEHmCa_QFqzE8K0wljZiYq--Qd9SCsudTwnWi7q5wqhKtXsqYApZ4R4bIYzt5Pnqjy3k-d28ir_-s8JjvRvWxWweyCuZUXIYYQlgNvf6osxVEv_Cf8F_fyqBA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2312475225</pqid></control><display><type>article</type><title>Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris</title><source>MEDLINE</source><source>PubMed Central</source><creator>Moore, Angela Yen ; Charles, Jean Elizze M ; Moore, Stephen</creator><creatorcontrib>Moore, Angela Yen ; Charles, Jean Elizze M ; Moore, Stephen</creatorcontrib><description>Sarecycline is a novel, narrow-spectrum, once-daily tetracycline-derived oral antibiotic that is FDA-approved in the US to be taken with or without food for moderate-to-severe acne vulgaris for ages 9 years of age and older. Sarecycline possesses anti-inflammatory properties and potent activity against Gram-positive bacteria, including activity against multiple strains of
, while exhibiting minimal activity against enteric aerobic Gram-negative bacteria. Unlike many acne studies, sarecycline was investigated for chest and back acne. Significant reduction in inflammatory lesions was seen at week 12 at 1.5 mg/kg/day of sarecycline, with statistically significant improvement seen as early as week 3. No reports of phototoxicity, dizziness, pseudotumor cerebri or lupus but 1.2% nausea and 1.2% vaginal candidiasis was reported in the pivotal Phase III studies.</description><identifier>ISSN: 1746-0913</identifier><identifier>EISSN: 1746-0921</identifier><identifier>DOI: 10.2217/fmb-2019-0199</identifier><identifier>PMID: 31475868</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Acne ; Acne Vulgaris - drug therapy ; Acne Vulgaris - microbiology ; Antacids ; Anti-Bacterial Agents - therapeutic use ; Anti-inflammatory agents ; Anti-Inflammatory Agents - therapeutic use ; Antibiotics ; Bacteria ; Bacteria - drug effects ; Bioavailability ; Blood-brain barrier ; Candidiasis ; Clinical Trials, Phase III as Topic ; Cystic fibrosis ; FDA approval ; Food ; Gram-Negative Aerobic Bacteria - drug effects ; Gram-negative bacteria ; Gram-positive bacteria ; Gram-Positive Bacteria - drug effects ; Humans ; Inflammation ; Microbial Sensitivity Tests ; Microbiota ; narrow spectrum ; Nausea ; Phototoxicity ; Propionibacteriaceae - drug effects ; Pseudotumors ; Review ; sarecycline ; Statistical analysis ; Studies ; tetracycline ; Tetracyclines - therapeutic use ; Vagina</subject><ispartof>Future microbiology, 2019-09, Vol.14 (14), p.1235-1242</ispartof><rights>2019 Angela Moore</rights><rights>2019. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 Angela Moore 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-1235d06e0b7864514fcba4604e668109b45b5e9e8f495d2d6f193dd31e8a80143</citedby><cites>FETCH-LOGICAL-c465t-1235d06e0b7864514fcba4604e668109b45b5e9e8f495d2d6f193dd31e8a80143</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802708/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802708/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31475868$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moore, Angela Yen</creatorcontrib><creatorcontrib>Charles, Jean Elizze M</creatorcontrib><creatorcontrib>Moore, Stephen</creatorcontrib><title>Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris</title><title>Future microbiology</title><addtitle>Future Microbiol</addtitle><description>Sarecycline is a novel, narrow-spectrum, once-daily tetracycline-derived oral antibiotic that is FDA-approved in the US to be taken with or without food for moderate-to-severe acne vulgaris for ages 9 years of age and older. Sarecycline possesses anti-inflammatory properties and potent activity against Gram-positive bacteria, including activity against multiple strains of
, while exhibiting minimal activity against enteric aerobic Gram-negative bacteria. Unlike many acne studies, sarecycline was investigated for chest and back acne. Significant reduction in inflammatory lesions was seen at week 12 at 1.5 mg/kg/day of sarecycline, with statistically significant improvement seen as early as week 3. No reports of phototoxicity, dizziness, pseudotumor cerebri or lupus but 1.2% nausea and 1.2% vaginal candidiasis was reported in the pivotal Phase III studies.</description><subject>Acne</subject><subject>Acne Vulgaris - drug therapy</subject><subject>Acne Vulgaris - microbiology</subject><subject>Antacids</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Anti-inflammatory agents</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antibiotics</subject><subject>Bacteria</subject><subject>Bacteria - drug effects</subject><subject>Bioavailability</subject><subject>Blood-brain barrier</subject><subject>Candidiasis</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>Cystic fibrosis</subject><subject>FDA approval</subject><subject>Food</subject><subject>Gram-Negative Aerobic Bacteria - drug effects</subject><subject>Gram-negative bacteria</subject><subject>Gram-positive bacteria</subject><subject>Gram-Positive Bacteria - drug effects</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Microbial Sensitivity Tests</subject><subject>Microbiota</subject><subject>narrow spectrum</subject><subject>Nausea</subject><subject>Phototoxicity</subject><subject>Propionibacteriaceae - drug effects</subject><subject>Pseudotumors</subject><subject>Review</subject><subject>sarecycline</subject><subject>Statistical analysis</subject><subject>Studies</subject><subject>tetracycline</subject><subject>Tetracyclines - therapeutic use</subject><subject>Vagina</subject><issn>1746-0913</issn><issn>1746-0921</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kc9vFCEUx4mxsbV69GpIvHgZBQYY8GDSNP5KmvTQeiYM82inmRnWB7Om_71sdt2oiQcC5H345j0-hLzi7J0QvHsf574RjNumLvuEnPFO6oZZwZ8ez7w9Jc9zfmBMGW75M3Lactkpo80Z8TceITyGaVzgA_V08YjpJ80bCAXXmRYo6A91GhPScg-0IPgyw1JoinROA6Av0JTUZNgCAvWhwtt1uvM45hfkJPopw8vDfk6-f_50e_m1ubr-8u3y4qoJUqvScNGqgWlgfWe0VFzG0HupmQStDWe2l6pXYMFEadUgBh25bYeh5WC8YVy25-TjPnez9jMMobaHfnIbHGePjy750f1dWcZ7d5e2ThsmOmZqwNtDAKYfK-Ti5jEHmCa_QFqzE8K0wljZiYq--Qd9SCsudTwnWi7q5wqhKtXsqYApZ4R4bIYzt5Pnqjy3k-d28ir_-s8JjvRvWxWweyCuZUXIYYQlgNvf6osxVEv_Cf8F_fyqBA</recordid><startdate>20190901</startdate><enddate>20190901</enddate><creator>Moore, Angela Yen</creator><creator>Charles, Jean Elizze M</creator><creator>Moore, Stephen</creator><general>Future Medicine Ltd</general><scope>FUMOA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190901</creationdate><title>Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris</title><author>Moore, Angela Yen ; Charles, Jean Elizze M ; Moore, Stephen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-1235d06e0b7864514fcba4604e668109b45b5e9e8f495d2d6f193dd31e8a80143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acne</topic><topic>Acne Vulgaris - drug therapy</topic><topic>Acne Vulgaris - microbiology</topic><topic>Antacids</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Anti-inflammatory agents</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antibiotics</topic><topic>Bacteria</topic><topic>Bacteria - drug effects</topic><topic>Bioavailability</topic><topic>Blood-brain barrier</topic><topic>Candidiasis</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>Cystic fibrosis</topic><topic>FDA approval</topic><topic>Food</topic><topic>Gram-Negative Aerobic Bacteria - drug effects</topic><topic>Gram-negative bacteria</topic><topic>Gram-positive bacteria</topic><topic>Gram-Positive Bacteria - drug effects</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Microbial Sensitivity Tests</topic><topic>Microbiota</topic><topic>narrow spectrum</topic><topic>Nausea</topic><topic>Phototoxicity</topic><topic>Propionibacteriaceae - drug effects</topic><topic>Pseudotumors</topic><topic>Review</topic><topic>sarecycline</topic><topic>Statistical analysis</topic><topic>Studies</topic><topic>tetracycline</topic><topic>Tetracyclines - therapeutic use</topic><topic>Vagina</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moore, Angela Yen</creatorcontrib><creatorcontrib>Charles, Jean Elizze M</creatorcontrib><creatorcontrib>Moore, Stephen</creatorcontrib><collection>Future Medicine (Open Access)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Future microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moore, Angela Yen</au><au>Charles, Jean Elizze M</au><au>Moore, Stephen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris</atitle><jtitle>Future microbiology</jtitle><addtitle>Future Microbiol</addtitle><date>2019-09-01</date><risdate>2019</risdate><volume>14</volume><issue>14</issue><spage>1235</spage><epage>1242</epage><pages>1235-1242</pages><issn>1746-0913</issn><eissn>1746-0921</eissn><abstract>Sarecycline is a novel, narrow-spectrum, once-daily tetracycline-derived oral antibiotic that is FDA-approved in the US to be taken with or without food for moderate-to-severe acne vulgaris for ages 9 years of age and older. Sarecycline possesses anti-inflammatory properties and potent activity against Gram-positive bacteria, including activity against multiple strains of
, while exhibiting minimal activity against enteric aerobic Gram-negative bacteria. Unlike many acne studies, sarecycline was investigated for chest and back acne. Significant reduction in inflammatory lesions was seen at week 12 at 1.5 mg/kg/day of sarecycline, with statistically significant improvement seen as early as week 3. No reports of phototoxicity, dizziness, pseudotumor cerebri or lupus but 1.2% nausea and 1.2% vaginal candidiasis was reported in the pivotal Phase III studies.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>31475868</pmid><doi>10.2217/fmb-2019-0199</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1746-0913 |
| ispartof | Future microbiology, 2019-09, Vol.14 (14), p.1235-1242 |
| issn | 1746-0913 1746-0921 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6802708 |
| source | MEDLINE; PubMed Central |
| subjects | Acne Acne Vulgaris - drug therapy Acne Vulgaris - microbiology Antacids Anti-Bacterial Agents - therapeutic use Anti-inflammatory agents Anti-Inflammatory Agents - therapeutic use Antibiotics Bacteria Bacteria - drug effects Bioavailability Blood-brain barrier Candidiasis Clinical Trials, Phase III as Topic Cystic fibrosis FDA approval Food Gram-Negative Aerobic Bacteria - drug effects Gram-negative bacteria Gram-positive bacteria Gram-Positive Bacteria - drug effects Humans Inflammation Microbial Sensitivity Tests Microbiota narrow spectrum Nausea Phototoxicity Propionibacteriaceae - drug effects Pseudotumors Review sarecycline Statistical analysis Studies tetracycline Tetracyclines - therapeutic use Vagina |
| title | Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T09%3A07%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sarecycline:%20a%20narrow%20spectrum%20tetracycline%20for%20the%20treatment%20of%20moderate-to-severe%20acne%20vulgaris&rft.jtitle=Future%20microbiology&rft.au=Moore,%20Angela%20Yen&rft.date=2019-09-01&rft.volume=14&rft.issue=14&rft.spage=1235&rft.epage=1242&rft.pages=1235-1242&rft.issn=1746-0913&rft.eissn=1746-0921&rft_id=info:doi/10.2217/fmb-2019-0199&rft_dat=%3Cproquest_pubme%3E2283289472%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2312475225&rft_id=info:pmid/31475868&rfr_iscdi=true |